Merus Labs International (TSE:MSL) Rating Increased to Strong-Buy at Leerink Partners

Leerink Partners upgraded shares of Merus Labs International (TSE:MSL) (NASDAQ:MSLI) to a strong-buy rating in a research report report published on Monday,Zacks.com reports.

Separately, Cantor Fitzgerald upgraded shares of Merus Labs International to a “strong-buy” rating in a report on Wednesday, March 11th. Two investment analysts have rated the stock with a Strong Buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Strong Buy”.

Merus Labs International Stock Performance

Merus Labs International has a 1-year low of C$0.95 and a 1-year high of C$1.76.

Merus Labs International Company Profile

Merus Labs International Inc is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company’s products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin. Elantan are tablets or capsules that belong to a group of medicines called organic nitrates. Isoket belongs to a group of medicines called organic nitrates. Deponit belongs to a group of medicines called nitrates.